Jiancheng Cheng1, Xianwu Zhou2, Xionggang Jiang3, Tucheng Sun4. 1. Department of Cardiothoracic Surgery, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China. 2. Department of Cardiovascular Surgery, Wuhan Asia Heart Hospital, Wuhan 430015, China. 3. Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 4. Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Abstract
BACKGROUND: Mutation of the ACTA2 (α-2 smooth muscle actin) gene accounts for ~15% of all cases of familial thoracic aortic aneurysms and dissections. Surprisingly, no severe vascular phenotypes were observed at baseline in mice carrying this gene mutation. Our aim was to explore whether mutation of ACTA2 promotes the development of aneurysms or dissections in the presence of angiotensin II (AngII) and to determine whether this mutation has an impact on the phenotypic modulation and apoptosis mediated by AngII in vascular smooth muscle cells (VSMCs). METHODS: Mice were divided into three groups: AngII stimulated-wild-type (WT) (AngII) and ACTA2-/- mice (ACTA2) group, in which AngII were administered subcutaneously into 8-week-old C57 mice and ACTA2-/- mice, respectively, for 4 weeks using osmotic minipumps, and the control group (WT), in which the WT mice were infused with normal saline (NS). Ultrasound was performed to quantify lumen diameters. RT-qPCR and Western blot were used to assess gene expression, and histobiochemistry was used to evaluate the pathological changes in the thoracoabdominal aortas. TUNEL was used to assess apoptosis in VSMCs. RESULTS: Compared with the AngII- group, the ACTA2 mice exhibited more severity of dilated lumena of the aortas, a significantly increased expression of osteopontin (OPN), an elevated ratio of Bax/Bcl-2, increased apoptosis, and a decreased expression of α-smooth muscle actin (α-SMA). CONCLUSIONS: Knockout of ACTA2 promoted AngII induced progressive lumen dilation of the aortas, apoptosis, and the phenotypic modulation in VSMCs in mice.
BACKGROUND: Mutation of the ACTA2 (α-2 smooth muscle actin) gene accounts for ~15% of all cases of familial thoracic aortic aneurysms and dissections. Surprisingly, no severe vascular phenotypes were observed at baseline in mice carrying this gene mutation. Our aim was to explore whether mutation of ACTA2 promotes the development of aneurysms or dissections in the presence of angiotensin II (AngII) and to determine whether this mutation has an impact on the phenotypic modulation and apoptosis mediated by AngII in vascular smooth muscle cells (VSMCs). METHODS: Mice were divided into three groups: AngII stimulated-wild-type (WT) (AngII) and ACTA2-/- mice (ACTA2) group, in which AngII were administered subcutaneously into 8-week-old C57 mice and ACTA2-/- mice, respectively, for 4 weeks using osmotic minipumps, and the control group (WT), in which the WT mice were infused with normal saline (NS). Ultrasound was performed to quantify lumen diameters. RT-qPCR and Western blot were used to assess gene expression, and histobiochemistry was used to evaluate the pathological changes in the thoracoabdominal aortas. TUNEL was used to assess apoptosis in VSMCs. RESULTS: Compared with the AngII- group, the ACTA2 mice exhibited more severity of dilated lumena of the aortas, a significantly increased expression of osteopontin (OPN), an elevated ratio of Bax/Bcl-2, increased apoptosis, and a decreased expression of α-smooth muscle actin (α-SMA). CONCLUSIONS: Knockout of ACTA2 promoted AngII induced progressive lumen dilation of the aortas, apoptosis, and the phenotypic modulation in VSMCs in mice.
Authors: Cay M Kielty; Clair Baldock; David Lee; Matthew J Rock; Jane L Ashworth; C Adrian Shuttleworth Journal: Philos Trans R Soc Lond B Biol Sci Date: 2002-02-28 Impact factor: 6.237
Authors: Ellen S Regalado; Dong-chuan Guo; Siddharth Prakash; Tracy A Bensend; Kelly Flynn; Anthony Estrera; Hazim Safi; David Liang; James Hyland; Anne Child; Gavin Arno; Catherine Boileau; Guillaume Jondeau; Alan Braverman; Rocio Moran; Takayuki Morisaki; Hiroko Morisaki; Reed Pyeritz; Joseph Coselli; Scott LeMaire; Dianna M Milewicz Journal: Circ Cardiovasc Genet Date: 2015-03-10
Authors: Jessica E Wagenseil; Nandan L Nerurkar; Russell H Knutsen; Ruth J Okamoto; Dean Y Li; Robert P Mecham Journal: Am J Physiol Heart Circ Physiol Date: 2005-04-29 Impact factor: 4.733
Authors: D Y Li; G Faury; D G Taylor; E C Davis; W A Boyle; R P Mecham; P Stenzel; B Boak; M T Keating Journal: J Clin Invest Date: 1998-11-15 Impact factor: 14.808
Authors: Vinamr Rastogi; Sanne J M Stefens; Judith Houwaart; Hence J M Verhagen; Jorg L de Bruin; Ingrid van der Pluijm; Jeroen Essers Journal: Front Med (Lausanne) Date: 2022-04-15
Authors: Matthew R Bersi; Víctor A Acosta Santamaría; Karl Marback; Paolo Di Achille; Evan H Phillips; Craig J Goergen; Jay D Humphrey; Stéphane Avril Journal: Sci Rep Date: 2020-06-08 Impact factor: 4.379
Authors: Jacob Greenway; Nicole Gilreath; Sagar Patel; Tetsuo Horimatsu; Mary Moses; David Kim; Lauren Reid; Mourad Ogbi; Yang Shi; Xin-Yun Lu; Mrinal Shukla; Richard Lee; Yuqing Huo; Lufei Young; Ha Won Kim; Neal L Weintraub Journal: Front Cardiovasc Med Date: 2020-10-30
Authors: Karlijn B Rombouts; Tara A R van Merrienboer; Johannes C F Ket; Natalija Bogunovic; Jolanda van der Velden; Kak Khee Yeung Journal: Eur J Clin Invest Date: 2021-11-21 Impact factor: 5.722